62724-32-7

Usage

Uses

Used in Pharmaceutical Industry:
Didemethylclomipramine is used as an active pharmaceutical ingredient for the treatment of depression and obsessive-compulsive disorder. Its ability to inhibit serotonin reuptake helps to alleviate symptoms associated with these conditions, improving the overall quality of life for patients.
Used in Research and Development:
In the field of neuroscience and pharmacology, didemethylclomipramine is used as a research compound to study the effects of serotonin reuptake inhibition on mood and behavior. This helps researchers to better understand the underlying mechanisms of depression and anxiety, and to develop more effective treatments for these disorders.
Used in Drug Interaction Studies:
Didemethylclomipramine is also used in drug interaction studies to evaluate the potential effects of combining it with other medications. This is important for ensuring patient safety and for optimizing treatment regimens, as some medications may interact with didemethylclomipramine and alter its efficacy or cause adverse effects.
Overall, didemethylclomipramine is a valuable compound in the pharmaceutical industry, with applications in the treatment of mood and anxiety disorders, as well as in research and drug interaction studies. Its role as a Serotonin reuptake inhibitor makes it a key component in the development of effective therapies for depression and obsessive-compulsive disorder.

InChI:InChI=1/C17H19ClN2/c18-15-9-8-14-7-6-13-4-1-2-5-16(13)20(11-3-10-19)17(14)12-15/h1-2,4-5,8-9,12H,3,6-7,10-11,19H2

Upstream product

• 1423077-06-8 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-3-oxopropanenitrile 
• 32943-25-2 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine 
• 726140-60-9 2-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethanone 

Downstream Products

• 1423077-49-9 N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-4-(trifluoromethoxy)benzenesulfonamide 

Relevant academic research and scientific papers

Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment

A series of 10,11-dihydro-5H-dibenzo [b,f]azepine hydroxamates (4–15) were synthesized, behaving as histone deacetylase inhibitors, and examined for their influence on vascular cognitive impairment (VCI), which correlated with dementia. The results reveal

TRICYCLIC MODULATORS OF PP2A

Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease and cardiac hypertrophy. The compounds are of formula (I)

HECT E3 LIGASE INHIBITORS AND USES THEREOF

The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising compounds of formu

Reengineered tricyclic anti-cancer agents

The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect. Reengineering these agents (TFP, CPZ, CIP) by replacing the basic amine with a neutral polar functional group (e.g., RTC-1, RTC-2) abrogated their CNS effects as demonstrated by in vitro pharmacological assays and in vivo behavioral models. Further optimization generated several phenothiazines and dibenzazepines with improved anti-cancer potency, exemplified by RTC-5. This new lead demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.